Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus A METHAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus A METHAPRED.
A-HYDROCORT vs A-METHAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Category C
Category C
Corticosteroid
Corticosteroid